Ten Years Milestones in Xanthine Oxidase Inhibitors Discovery: Febuxostat-Based Inhibitors Trends, Bifunctional Derivatives, and Automatized Screening Assays
Xanthine oxidase (XO) is an enzyme involved in the oxidative process of hypoxanthine and xanthine to uric acid (UA). This process also produces reactive oxygen species (ROS) as byproducts. Both UA and ROS are dangerous for human health, and some health conditions trigger upregulation of XO activity,...
Main Authors: | Miguel F. S. de Abreu, Camila A. Wegermann, Millena S. Ceroullo, Isabella G. M. Sant’Anna, Renato C. S. Lessa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Organics |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-401X/3/4/26 |
Similar Items
-
Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
by: Dewi C, et al.
Published: (2023-09-01) -
Comparison of Xanthine Oxidase Inhibitory Effect of Swertia chirayita and Febuxostat in Vitro
by: Qura-Tul-Ain, et al.
Published: (2021-04-01) -
The Xanthine Oxidase Inhibitor Febuxostat Suppresses Adipogenesis and Activates Nrf2
by: Yoshiki Higa, et al.
Published: (2023-01-01) -
Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
by: Yang Bai, et al.
Published: (2023-09-01) -
FEBUXOSTAT FOR TREATMENT OF CHRONIC HYPERURICEMIA IN GOUT PATIENTS
by: M. S. Petrova, et al.
Published: (2017-11-01)